Tofacitinib in Vogt-Koyanagi-Harada disease

Majumder, Parthopratim Dutta; Shah, Amravi; Kaushik, Viswanath

doi:10.4103/ijo.ijo_998_20

Cited by 12 publications

(16 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, there are initial reports of a favorable clinical response of ocular inflammation to tofacitinib. In two patients from a single previous publication (refractory uveitis and scleritis), where tofacitinib was used in combination with methotrexate,[ 6 ] as well as, in one patient in a recent publication[ 7 ](Vogt–Koyanagi–Harada Disease), where tofacitinib was used in combination with oral prednisolone, clinical effect of tofacitinib was noted approximately 4 weeks after the initiation of therapy and this is similar to the previous experience in RA. [ 4 ] An 8-week administration of topical tofacitinib has been reported to be well tolerated with reduction of markers of ocular surface inflammation in dry eye disease.…”

supporting

confidence: 80%

Commentary: Janus kinase inhibitors and their use in autoimmune ocular inflammatory disorders

Moreker¹

2020

Indian J Ophthalmol

View full text Add to dashboard Cite

supporting

confidence: 80%

Commentary: Janus kinase inhibitors and their use in autoimmune ocular inflammatory disorders

Moreker¹

2020

Indian J Ophthalmol

View full text Add to dashboard Cite

“…Dutta Majumder et al 19 reported a case of a young girl with exudative retinal detachment due to Vogt-Koyanagi-Harada disease that was steroid-resistant. One month after the initiation of TOFA, her visual acuity improved and fundus examination revealed resolution of exudative retinal detachment.…”

Section: Resultsmentioning

confidence: 99%

Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review

Álvarez-Reguera

Prieto-Peña

Herrero-Morant

et al. 2022

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Blau syndrome (BS) is an autoinflammatory disorder characterized by non-caseating granulomatous dermatitis, arthritis, and uveitis. We present a case of refractory and severe BS that was treated with the Janus kinase inhibitors (JAKINIBS), Tofacitinib (TOFA) and then Baricitinib (BARI). Our aim was to describe the clinical and immunological outcomes after treatment with JAKINIBS. Blood tests and serum samples were obtained during follow-up with TOFA and BARI. We assessed their effects on clinical outcomes, acute phase reactants, absolute lymphocyte counts (ALCs), lymphocyte subset counts, immunoglobulins, and cytokine levels. A review of the literature on the use of JAKINIBS for the treatment of uveitis and sarcoidosis was also conducted. TOFA led to a rapid and maintained disease control and a steroid-sparing effect. A decrease from baseline was observed in ALC, CD3+, CD4+, CD8+, and natural killer (NK) cell counts. B-cells were stable. Serum levels of interleukin (IL)-4 and tumor necrosis factor alpha (TNF-α) increased, whereas IL-2, IL-6, IL-10, and IL-17 maintained stable. TOFA was discontinued after 19 months due to significant lymphopenia. The initiation of BARI allowed maintaining adequate control of disease activity with an adequate safety profile. The literature review showed seven patients with uveitis and five with sarcoidosis treated with JAKINIBS. No cases of BS treated with JAKINIBS were found. We report the successful use of JAKINIBS in a patient with refractory and severe BS.

show abstract

“…At present, very little evidence is available on the use of JAK inhibitors for the treatment of ocular inflammation (17)(18)(19)(20)(21). Miserocchi et al reported that baricitinib and tofacitinib showed a significant reduction in inflammatory activity in uveitis than in systemic arthritis when four cases of juvenile idiopathic arthritis-associated uveitis (JIAU) refractory to csDMARD and bDMARD were investigated (17).…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report

et al. 2022

View full text Add to dashboard Cite

Baricitinib is a Janus kinase (JAK) inhibitor used to treat refractory rheumatoid arthritis and blocks the subtypes JAK1 and JAK2. A 35-year-old man with seronegative rheumatoid arthritis complicated by bilateral severe non-granulomatous panuveitis was resistant to steroid treatment, multiple conventional disease-modifying antirheumatic drugs (methotrexate and salazosulfapyridine), and TNF-α inhibitors (adalimumab and infliximab). Therefore, the TNF-α inhibitors were switched to baricitinib to decrease the activity of systemic arthritis. Along with the amelioration of inflammatory activity in seronegative rheumatoid arthritis, the inflammatory activity of uveitis was decreased. Vitreous opacity, serous retinal detachment, and anterior chamber cells showed improvement. Baricitinib was effective not only in refractory systemic arthritis but also in uveitis, which may provide a new treatment option for patients with refractory uveitis.

show abstract

Tofacitinib in Vogt-Koyanagi-Harada disease

Cited by 12 publications

References 3 publications

Commentary: Janus kinase inhibitors and their use in autoimmune ocular inflammatory disorders

Commentary: Janus kinase inhibitors and their use in autoimmune ocular inflammatory disorders

Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report

Contact Info

Product

Resources

About